AN2 Therapeutics, Inc. Stock Price, News & Analysis

AN2 Therapeutics (ANTX) reported Q1 2025 financial results and pipeline updates. The company ended Q1 with $78.5 million in cash and investments, extending runway into 2028. Key highlights include:

Pipeline developments:

• Initiated Phase 1 study for AN2-502998 in Chagas disease, with potential $1 billion peak sales
• Planning Phase 2 study of epetraborole for melioidosis
• Advancing epetraborole for M. abscessus NTM lung disease
• Developing oncology programs targeting ENPP1 and PI3Kα

Financial results show reduced losses with net loss of $10.6 million vs $16.6 million in Q1 2024. R&D expenses decreased to $7.7 million from $14.7 million, while G&A expenses slightly increased to $3.8 million from $3.6 million.

AN2 Therapeutics (NASDAQ: ANTX) reported that its Phase 3 EBO-301 study for epetraborole in MAC lung disease failed to meet its primary endpoint. Despite this setback, the company is pivoting focus to its broader boron chemistry pipeline. Key developments include: Pipeline Updates: - Initiated Phase 1 study of AN2-502998 for Chagas disease, with estimated $1B peak sales potential - Planning Phase 2 study for epetraborole in melioidosis in 2H25 - Pursuing M. abscessus lung disease treatment through non-dilutive funding - First oncology compounds targeting ENPP1 and PI3Kα expected to enter development in 2H25 Financial Position: - $78.5M cash position as of March 31, 2025 - Extended cash runway into 2028 - Implemented strategic workforce reduction and operational optimization

AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry platform and small molecule therapeutics, has announced its participation in the upcoming 2025 Citizens JMP Life Sciences Conference in New York.

Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will engage in a fireside chat on May 7, 2025, at 9:00 am ET. The management team will also be available for one-on-one meetings during the conference, which runs from May 7-8, 2025.

Investors and interested parties can access the webcast through AN2 Therapeutics' website investor section, with a replay available for at least 30 days following the event.

AN2 Therapeutics (ANTX) reported its Q4 and full year 2024 financial results, highlighting key pipeline developments. The company expects Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease in Q2 2025. A Phase 1 study for AN2-502998 in Chagas disease is planned for mid-2025, while melioidosis trial data is expected in Q2 2025.

Financial highlights include cash position of $88.6 million as of December 31, 2024, expected to fund operations through 2027. Full-year 2024 R&D expenses were $40.5 million, down from $54.9 million in 2023. The company reported a net loss of $51.3 million for 2024, improved from $64.7 million in 2023.

The company amended its statistical analysis plan, selecting QOL-B respiratory domain as the primary efficacy endpoint for the Phase 3 epetraborole trial. Additionally, ANTX is advancing its boron chemistry platform with first oncology candidates expected in 2H25.

AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry platform-derived small molecule therapeutics, has announced its participation in the upcoming Leerink Partners Global Healthcare Conference.

Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will deliver a corporate overview on March 12, 2025, at 2:20 pm ET. The management team will also be available for one-on-one meetings during the conference.

Investors and interested parties can access the presentation webcast through the Investors section of AN2 Therapeutics' website. The replay will remain available for a minimum of 30 days after the presentation.

AN2 Therapeutics (NASDAQ: ANTX) has announced a strategic update for its Phase 3 EBO-301 trial in treatment-refractory MAC lung disease. The company has submitted an amended statistical analysis plan to the FDA, selecting the Quality of Life – Bronchiectasis (QOL-B) respiratory domain patient reported outcome as the primary efficacy endpoint.

In the Phase 2 study, epetraborole showed nominal statistical superiority versus placebo, with a difference in least squares mean change from baseline of 6.90 (p=0.0365). The company plans to unblind Phase 3 data in Q2 2025, which includes 97 completed subjects. If Phase 3 data confirms Phase 2 findings, AN2 will discuss potential registrational pathways with the FDA for this highly refractory population.

This approach aligns with FDA's 2023 Guidance for Industry on NTM drug development and follows the precedent of Insmed's confirmatory Arikayce study in treatment-naïve MAC patients.

AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry platform-derived small molecule therapeutics, has announced its participation in two major investor conferences in March 2025.

At the TD Cowen 45th Annual Health Care Conference, Co-Founder, Chairman, President and CEO Eric Easom will deliver a corporate overview on March 3, 2025, at 2:30 pm ET. The management team will also be available for one-on-one meetings.

The company will also attend the Leerink Partners Global Healthcare Conference on March 12, 2025, where management will conduct one-on-one meetings. The TD Cowen conference presentation will be webcasted and accessible through AN2 Therapeutics' website, with a replay available for at least 30 days post-presentation.

AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry-based small molecule therapeutics, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.

Eric Easom, who serves as Co-Founder, Chairman, President and CEO, will deliver a corporate overview at the virtual event on Wednesday, February 12, 2025, at 3:20 PM ET. Interested parties can access the presentation through a webcast available on the Investors section of AN2 Therapeutics' website. The presentation recording will remain accessible for a minimum of 30 days after the event.

AN2 Therapeutics (Nasdaq: ANTX), a biopharmaceutical company specializing in boron chemistry-based small molecule therapeutics, has announced its participation in two major investor conferences this December. The company will present at the 7th Annual Evercore HealthCONx Conference (December 3-5, 2024), where CEO Eric Easom will deliver a corporate overview on December 4. Additionally, management will attend Oppenheimer's Movers in Rare Disease Summit on December 12, 2024, for one-on-one meetings.

The Evercore presentation will be available via webcast on AN2 Therapeutics' website, with a replay accessible for 30 days afterward.